ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS) announced today that total revenues for the first quarter of 2007 grew by $14.2 million to $26.4 million from $12.2 million in the comparable period in 2006, driven primarily by a 125 percent increase in the number of doses of BioThrax® (Anthrax Vaccine Adsorbed) delivered during the quarter to the U.S. Department of Health and Human Services (HHS) for inclusion in the strategic national stockpile and to the U.S. Department of Defense (the DoD) for active immunization of military personnel.
